Lv11
60 积分 2023-11-28 加入
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
3小时前
已完结
Cadonilimab is effective and safe in recurrent cervical cancer
1个月前
已完结
Cadonilimab is effective and safe in recurrent cervical cancer
1个月前
已完结
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
2个月前
已完结
PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx
2个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2个月前
已完结
Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study
3个月前
已完结
Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations
5个月前
已完结
Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use
5个月前
已完结
Cancer-targeting antibody–drug conjugates drive dealmaking frenzy
5个月前
已完结
皖公网安备34019202002308
